BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
1W: -4.7%
1M: -7.0%
3M: -32.5%
YTD: +6.7%
1Y: +2.0%
$17.48
+0.59 (+3.49%)
After Hours: $17.85 (+0.37, +2.12%)
Weekly Expected Move ±6.3%
$15
$16
$17
$18
$19
Credit Risk of going bust: lower than 88% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Bicara Therapeutics Inc. Common Stock would be worth roughly what it owes.
Total debt $1.2M against a stock market value of $1.12B.
Distance to default 12.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.2M (short-term plus half of long-term), stock volatility 54.2%; Altman Z'' 11.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Bicara Therapeutics Inc. Common Stock would be worth roughly what it owes.
Total debt $1.2M against a stock market value of $1.12B.
Distance to default 12.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.2M (short-term plus half of long-term), stock volatility 54.2%; Altman Z'' 11.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.2B
52W Range13.7-30.99
Volume609,330
Avg Volume761,015
Beta-0.82
Dividend—
Analyst Ratings
Company Info
CEOClaire Mazumdar Clemon
Employees103
SectorHealthcare
IndustryBiotechnology
IPO Date2024-09-13
Websitebicara.com
116 Huntington Avenue
Boston, MA 02116
US
Boston, MA 02116
US
617-468-4219
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Latest News
352,904 Shares of Bicara Therapeutics Inc. $BCAX Purchased by Bank of America Corp DE
Legal & General Group Plc Makes New Investment in Bicara Therapeutics Inc. $BCAX
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cohlhepp Ryan | S-Sale | 14,058 | $22.77 | 2026-09-08 |
| Cohlhepp Ryan | S-Sale | 3,442 | $23.43 | 2026-09-08 |
| Larson Jennifer | A-Award | 285,000 | $24.63 | 2026-08-12 |
| Larson Jennifer | 0 | — | 2026-08-12 | |
| Hyep Ivan | S-Sale | 12,500 | $27.97 | 2026-08-10 |